C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
2015/05/12 by Mahmoud H Mosli, Mahmoud Mosli, Guangyong Zou +10 · 29 citations
Biochemistry, Genetics and Molecular Biology · Nursing · Medicine · #Inflammatory Bowel Disease #Infant Nutrition and Health #Microscopic Colitis
paper · doi:10.1038/ajg.2015.120
Abstract
OBJECTIVES: Persistent disease activity is associated with a poor prognosis in inflammatory bowel disease (IBD). Therefore, monitoring of patients with intent to suppress subclinical inflammation has emerged as a treatment concept. As endoscopic monitoring is invasive and resource intensive, identification of valid markers of disease activity is a priority. The objective was to evaluate the diagnostic accuracy of C-reactive protein (CRP), fecal calprotectin (FC), and stool lactoferrin (SL) for assessment of endoscopically defined disease activity in IBD. METHODS: Databases were searched from inception to November 6, 2014 for relevant cohort and case-control studies that evaluated the diagnostic accuracy of CRP, FC, or SL and used endoscopy as a gold standard in patients with symptoms consistent with active IBD. Sensitivities and specificities were pooled to generate operating property estimates for each test using a bivariate diagnostic meta-analysis. RESULTS: Nineteen studies (n=2499 patients) were eligible. The pooled sensitivity and specificity estimates for CRP, FC, and SL were 0.49 (95% confidence interval (CI) 0.34-0.64) and 0.92 (95% CI 0.72-0.96), 0.88 (95% CI 0.84-0.90) and 0.73 (95% CI 0.66-0.79), and 0.82 (95% CI 0.73-0.88) and 0.79 (95% CI 0.62-0.89), respectively. FC was more sensitive than CRP in both diseases and was more sensitive in ulcerative colitis than Crohn's disease. CONCLUSIONS: Although CRP, FC, and SL are useful biomarkers, their value in managing individual patients must be considered in specific clinical contexts.
Cited by
- ACG Clinical Guideline Update: Ulcerative Colitis in Adults
- A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
- Calprotectin: from biomarker to biological function
- Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC. [europepmc]
- Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. [europepmc]
- Ulcerative colitis. [europepmc]
- Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). [europepmc]
- Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. [europepmc]
- Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. [europepmc]
- Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. [europepmc]
- Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis. [europepmc]
- AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. [europepmc]
- Gut microbiome structure and metabolic activity in inflammatory bowel disease. [europepmc]
- Evaluating Metagenomic Prediction of the Metaproteome in a 4.5-Year Study of a Patient with Crohn's Disease. [europepmc]
- A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. [europepmc]
- Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease. [europepmc]
- Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. [europepmc]
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. [europepmc]
- The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease. [europepmc]
- Management of Crohn Disease: A Review. [europepmc]
- Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. [europepmc]
- Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. [europepmc]
- Calprotectin: from biomarker to biological function. [europepmc]
- Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. [europepmc]
- Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. [europepmc]
- Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update. [europepmc]
- Serum amyloid protein A in inflammatory bowel disease: from bench to bedside. [europepmc]
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians. [europepmc]
Related